• Explore /
  • Poster
  • / Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

Abstract Poster

Authors

null

Yutaka Ogata

Department of Surgery, Kurume Medical Center, Kurume University School of Medicine, Kurume, Japan

Yutaka Ogata , Yoshito Akagi , Yoshihiro Kakeji , Yasunori Emi , Eiji Oki , Hiroshi Saeki , Tetsuo Touyama , Hironori Samura , Hideo Baba , Shoji Natsugoe , Kazuo Shirouzu , Shoji Tokunaga , Yoshihiko Maehara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000001312

Citation

J Clin Oncol 30, 2012 (suppl 4; abstr 602)

DOI

10.1200/jco.2012.30.4_suppl.602

Abstract #

602

Poster Bd #

E33

Abstract Disclosures

Similar Posters

First Author: Angela Damato

First Author: Sebastian Stintzing

First Author: Grant Richard Williams

First Author: Zev A. Wainberg